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The Maintenance of High Affinity Plasminogen Binding by Group A Streptococcal
Plasminogen-binding M-like Protein Is Mediated by Arginine and Histidine
Residues within the a1 and a2 Repeat Domains.
Abstract
Subversion of the plasminogen activation system is implicated in the virulence of group A streptococci
(GAS). GAS displays receptors for the human zymogen plasminogen on the cell surface, one of which is
the plasminogen-binding group A streptococcal M-like protein (PAM). The plasminogen binding domain of
PAM is highly variable, and this variation has been linked to host selective immune pressure. Site-directed
mutagenesis of full-length PAM protein from an invasive GAS isolate was undertaken to assess the
contribution of residues in the a1 and a2 repeat domains to plasminogen binding function. Mutagenesis
to alanine of key plasminogen binding lysine residues in the a1 and a2 repeats (Lys98 and Lys111) did not
abrogate plasminogen binding by PAM nor did additional mutagenesis of Arg101 and His102 and Glu104,
which have previously been implicated in plasminogen binding. Plasminogen binding was only abolished
with the additional mutagenesis of Arg114 and His115 to alanine. Furthermore, mutagenesis of both
arginine (Arg101 and Arg114) and histidine (His102 and His115) residues abolished interaction with
plasminogen despite the presence of Lys98 and Lys111 in the binding repeats. This study shows for the
first time that residues Arg101, Arg114, His102, and His115 in both the a1 and a2 repeat domains of PAM
can mediate high affinity plasminogen binding. These data suggest that highly conserved arginine and
histidine residues may compensate for variation elsewhere in the a1 and a2 plasminogen binding repeats,
and may explain the maintenance of high affinity plasminogen binding by naturally occurring variants of
PAM.
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Characterisation of the PAM binding site

The maintenance of high affinity plasminogen binding by group A
streptococcal plasminogen–binding M-like protein (PAM) is mediated
by arginine and histidine residues within the a1 and a2 repeat domains ∗
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Characterisation of the PAM binding site

Subversion of the plasminogen activation
system is implicated in the virulence of
group A streptococci (GAS). GAS display
receptors for the human zymogen
plasminogen on the cell surface, one of
which is the plasminogen-binding group A
streptococcal M-like protein (PAM). The
plasminogen binding domain of PAM is
highly variable, and this variation has been
linked to host selective immune pressure.
Site-directed mutagenesis of full length
PAM protein from an invasive GAS isolate
was undertaken to assess the contribution
of residues in the a1 and a2 repeat domains
to
plasminogen
binding
function.
Mutagenesis to alanine of key plasminogen
binding lysine residues in the a1 and a2
repeats (Lys98 and Lys111) did not abrogate
plasminogen binding by PAM, nor did
additional mutagenesis of Arg101 and His102
and Glu104, which have previously been
implicated
in
plasminogen
binding.
Plasminogen binding was only abolished
with the additional mutagenesis of Arg114
and His115 to alanine. Furthermore,
mutagenesis of both arginine (Arg101 and
Arg114) and histidine (His102 and His115)
residues
abolished
interaction
with
plasminogen despite the presence of Lys98
and Lys111 in the binding repeats. This
study shows for the first time that residues
Arg101, Arg114, His102 and His115 in both the
a1 and a2 repeat domains of PAM can
mediate high affinity plasminogen binding.
These data suggest that highly conserved
arginine and histidine residues may
compensate for variation elsewhere in the
a1 and a2 plasminogen binding repeats, and
may explain the maintenance of high
affinity plasminogen binding by naturally
occurring variants of PAM.
The Gram positive bacterium Streptococcus
pyogenes (group A streptococcus, GAS) 1 is
responsible for a wide variety of skin and
mucosal infections in humans. Current
estimates indicate that approximately 1.78
million new cases of severe streptococcal
infection occur each year (1). A key feature of
invasive GAS infections is the ability of the

organism to migrate from cutaneous and
mucosal surfaces to deep tissue sites, resulting
in severe invasive disease. The binding and
activation of plasminogen by GAS has been
implicated in the pathogenesis of this
organism (2).
Plasminogen is a single chain glycoprotein
found in plasma and extracellular fluids at
concentrations of approximately 2 μM (3).
Cleavage of plasminogen at a single site
(Arg560-Val561) by specific plasminogen
activators results in the formation of the twochain plasmin molecule, which contains a
serine protease active site in the C-terminal
region (4). Human plasminogen can also be
activated to plasmin by the GAS protein
streptokinase, as part of a highly species
specific plasminogen/streptokinase activator
complex (2). Plasmin has the ability to
degrade fibrin clots, connective tissue and the
extracellular matrix (3,4). Thus activation of
this proteolytic system by GAS may have
significant pathological consequences in the
host (5).
Isolated initially from M53 serotype GAS, the
plasminogen-binding group A streptococcal
M-like protein (PAM) is a 42 kDa molecule
which binds both plasmin and plasminogen
directly and with high affinity (Kd ~ 1 nM) (6).
A newly developed model of GAS infection
using mice expressing a human plasminogen
transgene indicates that plasminogen plays a
critical role in GAS infection, with a
significant increase in mortality observed in
transgenic mice when compared to wild type
littermate control mice (5). Additionally, the
PAM-positive GAS isolate AP53 exhibited a
60% increase in mortality in transgenic mice
when compared to wild type littermates, and a
PAM negative isogenic mutant of this strain
showed only minimal virulence in both wild
type and human plasminogen transgenic
murine backgrounds (5). Thus, it appears that
for a subset of GAS isolates, the ability of
PAM to focus plasminogen at the GAS cell
surface is crucial for virulence.
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Characterisation of the PAM binding site
The major plasmin(ogen)-binding site of PAM
is located in the N-terminal variable region of
the protein, and is comprised of two
characteristic tandem repeats designated a1
and a2. Similar binding motifs have been
identified in M-like proteins of other GAS
isolates associated with skin infection (6,7).
PAM has been implicated in the establishment
of GAS skin infections such as impetigo, and
the PAM genotype is almost exclusively
associated with the chromosomal emm pattern
D, which is considered a genetic marker for
skin tropic GAS (7-9). However, in the
Northern Territory of Australia, where
streptococcal skin infection is endemic and
high rates of invasive infection such as
bacteraemia have been reported (10), PAM
positive GAS are associated with a variety of
disease states (11). The plasminogen binding
domain of PAM has been shown to be highly
variable, however, this diversity does not
abrogate plasminogen binding by naturally
occurring PAM variants (12). This finding
may, in part, be due to the conservation of key
amino acid residues within the plasminogen
binding domain (11,12). Plasmin(ogen) is
known to interact with its ligands via preformed lysine binding-sites within the Nterminally located triple-disulfide bonded
kringle domains (4). Kringles 1, 4 and 5
display the highest affinity for lysine-based
ligands, with kringle 2 displaying the weakest
affinity (13). PAM lacks the typical Cterminal lysine residues characteristic of many
plasminogen receptors. Rather, internal lysine
residues in the a1 and a2 repeat regions of
PAM (Lys98 and Lys111) are thought to
mediate binding to kringle 2 of plasminogen
(14). Early reports suggested that Lys98 of the
a1 repeat contributed the majority of the
plasminogen binding ability of PAM (14).
However, studies involving a polypeptide
designated VEK-30 and a recombinant kringle
2 modified to contain a high affinity lysine
binding site, highlighted a potential role for
internal His102, Arg101 and Glu104 residues
within the a1 repeat in this interaction (15,16).
VEK-30 is comprised of the six residues
preceding the a1 repeat, the entire a1 repeat,
together with the first ten residues of the a2
repeat of PAM (17). The relative contribution

to binding by residues within the a1 and a2
repeat of the full length PAM protein to
plasminogen has not been characterised.
Here, we have undertaken site-directed
mutagenesis studies on the PAM molecule and
defined residues involved in the interaction
with plasminogen. These studies highlight the
important contribution of multiple arginine
and histidine residues within both the a1 and
a2 plasminogen binding domains and may
explain the capacity of naturally occurring
PAM variants to maintain high affinity
plasminogen binding despite considerable
variation observed in the plasminogen binding
repeats.
MATERIALS AND METHODS
Bacterial strains and culture methods Escherichia coli TOP10 containing pGEX2TPAMNS13 expression plasmids were grown on
Luria Bertani (LB) agar plates or cultured in
LB broth supplemented with ampicillin (100
μg/ml) as described previously (18). Plasmid
DNA was extracted for PCR and DNA
sequence analysis using the Wizard ® Plus SV
DNA purification kit (Promega, USA).
Site-directed mutagenesis - The PAM gene
from streptococcal strain NS13 (PAMNS13
GenBank™ AY351851), which is identical to
the prototype PAM sequence in the a1 and a2
repeat domain, had previously been cloned
into the expression vector pGEX2T (12). To
assess the role of specific binding-site residues
in the interaction of PAM with plasminogen,
site-specific mutations were introduced into
the PAMNS13 binding site. The wild type
construct (100 ng) was used as template DNA
to create site-directed mutants with the
QuickChange™ site-directed mutagenesis kit
(Stratagene, USA). PCR reactions consisted of
1x Pfu reaction buffer (Stratagene, USA),
0.25mM dNTPs (Boehringer Mannheim,
Germany), 2.5 U of Pfu Ultra polymerase
(Stratagene, USA), and 125 ng of each primer,
made up to a volume of 50 μl with dH2O.
Oligonucleotide Primers (Sigma-Aldrich)
were designed as per the manufacturers
instructions (Stratagene, USA). In general,
primers consisted of sequence encoding the
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desired mutation, flanked on either side by
fifteen nucleotides of wild type sequence. The
specific primer sequences are given in Table
1, with the introduced mutations underlined.
For site-directed mutants containing more than
two mutations not encoded by a single primer,
alanine residues were sequentially introduced
using previously mutated DNA as a template.
Following an initial denaturation step (95°C,
30 sec), PCR cycling parameters consisted of
sixteen cycles of 95°C for 30 sec, 55°C for 1
min and 68°C for 10 min. An additional 7 min
extension at 55°C was then performed. PCR
was conducted with a Cooled Palm 96
thermocycler (Corbett Research). Nonamplified template DNA was removed by
incubation of reactions for 1 h at 37°C
following the addition of Dpn I (10 U/ 50 μl
reaction). E. coli TOP10 (Invitrogen, USA)
were transformed with 150 ng of Dpn I
digested PCR product using standard
procedures (18).
DNA sequence analysis, expression and
purification of recombinant M proteins - DNA
sequence analysis was used to verify
introduced mutations and confirm the absence
of random mutations in site-directed mutants.
DNA sequence analysis was performed using
the primers listed in Table 1, and sequence
reactions undertaken using terminator ready
reaction mix (PE Applied Biosystems, USA).
DNA sequencing gels were prepared as per the
manufacturers
instructions
and
electrophoresed using an Applied Biosystems
3130 X Genetic Analyser (Applied
Biosystems, USA). Sequence data was
analysed using ABI Prism™ DNA sequencing
analysis software (Perkin Elmer, USA).
Recombinant proteins were expressed and
purified essentially as described previously
(12,19), from 1 L E. coli cultures, using
glutathione agarose (Sigma-Aldrich, USA)
and native Ni-NTA agarose (Qiagen,
Germany) affinity chromatography. Prior to
elution from the glutathione agarose column,
the GST tag was removed from the Nterminus of recombinant fusion proteins by the
addition of one column volume of thrombin
solution (1 U thrombin/μl, PBS pH 8.0). The

column was incubated for 5 h at room
temperature and the cleaved recombinant
protein eluted in PBS (pH 8.0). Each step of
the protein purification process was monitored
by
12%
SDS-polyacrylamide
gel
electrophoresis (PAGE) analysis (20), with
protein visualised using Coomassie R 250
staining.
Circular dichroism spectroscopy - To examine
potential variation in protein secondary
structure as a result of site-directed
mutagenesis, far UV Circular dichroism (CD)
spectra were obtained for both wild type and
mutant recombinant PAM proteins. CD
spectra were acquired using a Jasco J-810
Spectropolarimeter (Jasco, Canada) at room
temperature. CD spectra data was recorded
from 190 – 250 nm in a 1 cm pathlength cell
containing 1.5 ml of protein solution at a
concentration of 0.04 mg/ml in 10 mM sodium
phosphate buffer (pH 7.4). Recorded data
represents the average of six scans, corrected
for buffer baseline. Molar residue ellipticity
([θ]) was calculated using the following
formula:
[θ] = θ × 100 × Molecular weight /
concentration (mg/ml) × distance × Number of
amino acids (21) .
The percentage of α-helix was estimated from
the ellipticity at 222 nm using the following
formula: % α-helix = - (θ222 nm – 4,800)/45,400
(22).
Plasminogen purification and labeling - Gluplasminogen was purified from human plasma
using
lysine
Sepharose-4B
affinity
chromatography as described previously
(12,23).
Purified
plasminogen
was
biotinylated by the addition of 10% (v/v) 1 M
NaHCO3 (pH 9), and a 40 molar excess of
biotin-X-NHS in dimethyl sulfoxide (SigmaAldrich, USA). The reaction was incubated at
4°C overnight with mixing. Free biotin was
separated from biotinylated plasminogen by
PD-10
gel
filtration
chromatography
(Amersham Biosciences, USA) (12).
Plasminogen binding analysis - Solid phase
plasminogen binding assays were performed
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in order to assess the impact of introduced
mutations on protein function essentially as
previously described (12). Ninety-six well
microtitre plates (Greiner Bio-one, Germany)
were coated with 150 nM recombinant protein
(50 μl in 0.1 M NaHCO3) at 4°C overnight.
Following three washes with PiNT (50 mM
Na2HPO4, 150 mM NaCl, 0.05% Tween-80,
pH 7.5), plates were blocked with 50 μl of
blocking solution (1% skim milk powder,
PiNT) for 1 h at 37°C. Wells were washed as
above, and 500 nM biotinylated gluplasminogen was diluted in a three-fold
titration across the plate with blocking buffer,
in the presence or absence of a 50 fold molar
excess of unlabelled glu-plasminogen.
Plasminogen was allowed to bind to
immobilised proteins for 2 h at room
temperature.
For
competition
assays,
decreasing concentrations of unlabelled fluid
phase wild type PAMNS13 (25 μM-0.14 nM)
were allowed to compete with immobilised
proteins for binding to biotinylated gluplasminogen. Competitor was titrated threefold across the microtitre plate prior to the
addition of biotinylated glu-plasminogen to all
wells, at a final concentration of 500 nM. The
assay was incubated for 2 h at room
temperature. Following the plasminogen
incubation step, microtitre plates were washed
three times, and 50 μl of neutravidin
conjugated to horse radish peroxidase (Progen,
Australia) diluted 1:5000 with blocking
solution was added to all wells and incubated
for 2 h at room temperature. After five washes
with PiNT, the reactions were developed by
the addition of 50 μl o-phenylenediamine
(Sigma-Aldrich, USA) substrate (8 mM
Na2HPO4 pH5.0, 2.2mM o-phenylenediamine,
3% H2O2). Colour development was stopped
by the addition of 50 μl of 10 M hydrochloric
acid, and the plates were read at 490 nm using
a Spectramax 250 plate reader (Molecular
Devices, USA).
Data was normalised against the highest and
lowest absorbance value for each assay, and
non-linear regression analysis performed using
GraphPad® Prism (v4.00, GraphPad software,
CA). For the calculation of equilibrium

binding dissociation constants (Kd), a one
versus two site binding analysis was
conducted and the best-fit curve fitted to the
data. For competition experiments, a one-site
competition curve was fitted to the data from
which the effective concentration of
competitor required to inhibit binding by 50%
(EC50) was calculated.
Statistical analysis - For plasminogen binding
experiments, a one-way ANOVA was initially
used on all data, followed by an unpaired t-test
with Welsch’s correction to determine if there
was any significant difference in the Kd values
for plasminogen binding by PAM mutants and
PAMNS13.
RESULTS
The gene encoding wild type PAMNS13 shares
100% identity with the prototype PAM
sequence in the a1 and a2 repeat domain
responsible for the interaction with
plasminogen (11). In order to assess the role of
specific binding site residues in the interaction
of PAMNS13 with plasminogen, a number of
site-directed mutants were constructed in
which the residues of interest were replaced
with alanine. The binding site sequences of the
five constructed mutants are shown in Fig. 1A.
The presence of introduced mutations was
verified by DNA sequence analysis. Following
expression in E. coli, recombinant proteins of
approximately 40 kDa in size were purified
using glutathione-agarose and Ni-NTA
agarose affinity chromatography (Fig. 1B).
The impact of mutations in the a1 and a2
repeat domains of PAMNS13 on protein
structure were analysed using far UV CD
spectroscopy. All proteins used in this study
were found to have a CD emission spectrum
characteristic of α-helical coiled proteins (24),
displaying two characteristic minima at
approximately 210 nm and 220 nm, and a
maximum peak at 190 nm (Fig. 2). This is
similar to the CD spectra of other
streptococcal M proteins, which are coiledcoil α-helical proteins (22). Thus, even after
mutagenesis these proteins appear to maintain
an α-helical secondary structure. Additionally,
for all proteins the two minima are of a similar
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magnitude, which is indicative of coiled-coil
proteins (25). Percent α-helicity ranged from
27% to 44% (Table 2). CD analysis of other
streptococcal M proteins has found them to
contain between 23% and 70% α-helix
(22,26).
PAMNS13 has previously been shown to
interact with glu-plasminogen with high
affinity (Kd ~ 1 nM) (12). To determine the
impact of the introduced mutations in the
PAMNS13 binding site on plasminogen binding,
solid phase binding assays were performed
utilising biotinylated glu-plasminogen. The
recombinant
PAM
mutants
bound
plasminogen in a dose-dependant fashion, and
saturable binding was achieved with 500 nM
plasminogen for 3 of the 5 mutant proteins
after 2 h (Fig. 3). Non-linear regression
analysis was used to determine the affinity of
each recombinant protein for glu-plasminogen
(Table 2). Equilibrium dissociation constants
(Kd) were calculated using a best-fit non-linear
regression curve. The following site-directed
mutants where residues were replaced with
alanine, PAMNS13[K98 K111] and PAMNS13[K98
R101 H102 E104 K111], bound plasminogen with
Kd values of 10.34 nM and 50.24 nM
respectively. Whilst this represents a
significant decrease in affinity for gluplasminogen when compared to wild type
PAMNS13 ( Kd = 1.58 nM; p < 0.05), binding
by these mutants was still specific and
saturable.
PAMNS13[R101
H102]
bound
plasminogen with a Kd value of 1.69 nM,
which is not significantly different from that
of wild type PAMNS13 (p > 0.05). Only nonspecific plasminogen binding was seen for
mutants PAMNS13[K98 R101 H102 E104 K111 R114
H115] and PAMNS13[R101 H102 R114 H115],
indicating that the arginine and histidine
residues in both repeat domains are critical
residues in the interaction of PAM with
plasminogen.
To further explore the contribution of these
residues to the interaction with plasminogen,
competition binding experiments were
performed. The effective concentration of
competitor required to inhibit plasminogen
binding by 50% (EC50) was determined by

fitting a one-site competition curve (Fig. 4).
EC50 values ranged from 0.25 μM to 22.06
μM. This represents a greater than 90%
decrease in EC50 values for mutant proteins
PAMNS13[K98 K111], PAMNS13[K98 R101 H102
E104 K111] and PAMNS13[R101 H102], when
compared to wild type PAMNS13. As expected,
there was an inverse correlation between Kd
and EC50 (Table 2). These data indicate that
whilst mutation of residues Lys98, Arg101,
His102, Glu104 and Lys111 within the
plasminogen binding repeats of PAMNS13
decreases the avidity of the interaction with
plasminogen, the simultaneous mutation of
residues Arg101, His102, Arg114 and His115 is
required to fully abolish binding.
DISCUSSION
A key feature of certain strains of S. pyogenes
is the ability to migrate from cutaneous and
mucosal surfaces to deep tissue sites, resulting
in serious invasive infections such as
bacteraemia,
necrotising
fasciitis
and
streptococcal toxic shock-like syndrome. The
exact mechanisms of GAS invasive infection
have yet to be fully explained, however one
hypothesis involves the interaction of GAS
with the host plasminogen activation system.
Four GAS plasminogen binding proteins have
been described in the literature, as well as the
secreted plasminogen activator streptokinase
(2,27-29). The multiplicity of potential
virulence factors associated with S. pyogenes
that interact with the plasminogen activation
system necessitates a deeper understanding of
the relationship of GAS with plasminogen.
PAM is a cell surface exposed, high affinity
plasminogen receptor expressed by GAS
associated with a variety of disease states, and
appears to play an integral role in the
plasminogen-dependant virulence of PAM
positive GAS. In a recent study, it was shown
that elimination of PAM dependant
plasminogen binding by GAS significantly
reduced mortality in mice expressing the
human
plasminogen
transgene
(5).
Furthermore, whilst the plasminogen binding
domain of PAM is highly variable, this
variation does not appear to significantly
impact on the high affinity interaction of PAM
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with plasminogen. The conservation of
binding function in spite of sequence diversity
is indicative of the physiological significance
of this interaction, and the ability of GAS to
subvert the host plasminogen activation
system (12).
The a1 and a2 repeat domains in the Nterminus of PAM mediate binding to kringle 2
of plasminogen, with the a1 repeat residue
Lys98 generally considered to make the
greatest contribution to this interaction
(6,14,17). Using site-directed mutagenesis,
this study indicates that residues Arg101 and
His102 within the a1 repeat, together with
residues Arg114 and His115 within the a2 repeat,
are critical for the interaction of full length
PAM with plasminogen. The interaction with
plasminogen
of
site-directed
mutant
PAMNS13[K98 K111] in which residues Lys98
and Lys111 were mutated to alanines was dosedependant and specific. Additionally, the Kd
value for this interaction was within a
physiologically relevant concentration of
plasminogen, which circulates in the
bloodstream
at
a
concentration
of
approximately 2 μM (3). Furthermore,
mutation of binding site residues Arg101,
His102,
Arg114
and
His115
abolished
plasminogen binding by PAMNS13 despite the
presence of residues Lys98 and Lys111. To our
knowledge, this is the first demonstration of a
non-lysine-dependent, high affinity interaction
between plasminogen and a full-length
naturally occurring receptor.
Previous studies involving the interaction of a
polypeptide sequence designated VEK-30
with modified kringle 2 of plasminogen
highlighted the importance of PAM a1/a2
residues Lys98, Arg101, His102, Glu104 and
Lys111 in the peptide/plasminogen interaction
(15,16). Notably, VEK-30 lacks the final three
residues of the a2 repeat (Arg114, His115,
Glu116). Mutation of residues Lys98, Arg101,
His102, Glu104 and Lys111 in the full-length
protein PAMNS13 in this study did not eliminate
plasminogen binding. However, the avidity of
this interaction was significantly reduced, as
evidenced by a greater than 90% decrease in
EC50 values recorded for mutant proteins when

compared to wild type PAMNS13. This supports
the previous finding that these residues are
important in the interaction of PAM with
plasminogen. However, the finding that
mutation of arginine (Arg101 and Arg114) and
histidine (His102 and His115) residues in both
the a1 and a2 repeat was required to fully
abrogate plasminogen binding suggests that
both repeats are able to mediate high affinity
interactions with plasminogen. Residues
Arg101 and His102 of the a1 repeat of PAM
have been shown to make numerous saltbridge
and hydrophobic electrostatic interactions with
recombinant kringle 2, forming a pseudoligand similar to the lysine analogue ε- amino
caproic acid (16). It is thus likely that the
corresponding residues Arg114 and His115 in the
a2 repeat interact with plasminogen in a
similar fashion.
The decrease in plasminogen binding by sitedirected mutants reported here does not appear
to be due to loss of secondary structure, as all
site-directed mutants displayed CD spectra
characteristic of coiled-coil alpha-helical
proteins, similar to that of the wild type
PAMNS13. The percent α-helicity for mutants
reported here was between 27% and 44%. CD
analysis of other streptococcal M proteins has
found them to contain between 23% and 70%
α-helix (22, 26). However, the spectra for all
α-helical proteins are not identical due to the
small effect of non-aromatic side chains on the
rotary strength of the peptide bond, and
occasional helix distortions (24). It has also
been shown that the α-helical structure of the
peptide VEK-30, representative of the a1
repeat of PAM, increases from 25% to 75%
upon binding to kringle 2 of plasminogen (16).
It is possible that a similar structural shift
could occur in the full length PAM protein. No
correlation was seen between percent αhelicity and plasminogen binding function,
suggesting that any secondary structure
changes have had only a minor influence on
the differences in plasminogen binding
described here.
We have recently shown that whilst the
plasminogen binding domain of PAM is
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highly variable, this diversity does not
abrogate plasminogen binding by naturally
occurring PAM variants (12). In these
naturally occurring PAM variants, the Arg and
His residues in both a1 and a2 repeat domains
are highly conserved (11). Interestingly, in this
study, a loss of plasminogen binding was only
observed following simultaneous mutation of
both the Arg101 and His102 residues in the a1
repeat, and the Arg114 and His115 residues in
the a2 repeat. Therefore, conservation of Arg
and His residues in either repeat domain may
compensate for variation elsewhere in the
binding repeats, and explain the maintenance
of high affinity plasminogen binding by
naturally occurring variants of PAM.

Recent findings that the acquisition of
plasminogen by S. pyogenes may be crucial
for the virulence of certain strains of GAS, and
the ability of multiple GAS proteins to
facilitate this process, necessitates a deeper
understanding of the mechanisms via which
certain
GAS
proteins
interact
with
plasminogen. This study highlights for the first
time the importance of highly conserved
arginine (Arg101 and Arg114) and histidine
(His102 and His115) residues within the binding
site of the plasminogen binding protein PAM,
in mediating the interaction of this molecule
with plasminogen. Such a finding may have
implications for the identification of novel
plasminogen binding proteins in the future.
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streptococcal M-like protein; PCR, polymerase chain reaction; CD, circular dichroism; LB, Luria
Bertani; GST, glutathione S transferase; PBS, phosphate buffered saline; SDS, sodium dodecyl sulphate.
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Table 1. Forward primers used for PCR construction and DNA sequence analysis of
PAMNS13 site directed mutants. Underlined sequences indicate introduced mutations. For
site-directed mutants containing two or more mutations not encoded in a single primer,
mutations were sequentially introduced using previously mutated DNA as a template.
Introduced
Mutation
K98/A
K111/A
R101H102E104/A
R101H102/A
R114H115/A

Forward Mutagenesis Primer
5’-GATGCTGAGTTGCAACGACTTGCAAACGAGAGACATGAAGAAGCA-3’
5’-GAAGCAGAGTTGGAGCGACTTGCAAGCGAGAGACATGATCATGAC-3’
5’-CGACTTGCAAACGAGGCAGCAGAAGCAGCAGAGTTGGAGCGA-3’
5’-CGACTTGCAAACGAGGCAGCAGAAGCAGCAGAGTTGGAGCGA-3’
5’-CGACTTGCAAGCGAGGCAGCAGATCATGACAAAAAAGAAGC-3’

Primer
PAMF1
PAMR1
PAMF2
PAMR2
PAMF3
PAMR3
pGEX2TF
pGEX2TR

DNA Sequence Analysis Primers
5’-ATAAGCAAGAACATCTTGACGG-3’
5’-CTGTTAATTTCTTGCTTTC-3’
5’-AAAGGGCTTAAGACTGATTTAC-3’
5’-GACCAGCTAATTTGCTGTTTGC-3’
5’-GCAAACAGCAAATTAGCTGCTC-3’
5’-CTTCTCAACATCATCTTTAAGG-3’
5’-GGGCTGGCAAGCCACGTTTGGTG-3’
5’-CCGGGAGCTGCATGTGTCAGAGG-3’
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Table 2. Functional and structural characteristics of PAMNS13 site –directed mutants.
Protein

Kd (nM)

EC50 (μM)

PAMNS13
PAMNS13[K98K11]
PAMNS13[K98R101H102E104K111]
PAMNS13[K98R101H102E104K111R114H115]
PAMNS13[R101H102]
PAMNS13[R101H102R114H115]

1.58
10.34
50.24
Non-specific binding only
1.69
Non-specific binding only

22.06
0.57
0.25
Not determined
4.87
Not determined

% α helix
27
41
33
44
33
29
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Fig 1. A Alignment of the plasminogen binding domain of wild type PAMNS13 with the 5
site-directed mutants constructed in this study. Mutated residues are indicated in bold. B
12% SDS-PAGE gel showing the 6 purified recombinant proteins used in this study.
Lane 1, PAMNS13 ; lane 2, PAMNS13[K98 K111]; lane 3 PAMNS13[K98 R101 H102 E104 K111];
lane 4, PAMNS13[K98 R101 H102 E104 K111 R114 H115]; lane 5, PAMNS13[R101 H102]; lane 6,
PAMNS13[R101 H102 R114 H115]. Molecular weight markers are given in kilo Daltons (kDa).
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Fig 2. Circular dichroism spectra of recombinant PAMNS13 mutants. A PAMNS13; B
PAMNS13[K98 K111]; C PAMNS13[K98 R101 H102 E104 K111]; D PAMNS13[K98 R101 H102 E104
K111 R114 H115]; E PAMNS13[R101 H102]; F PAMNS13[R101 H102 R114 H115] All proteins
exhibit CD emission spectrum characteristic of α-helical coiled proteins (24), displaying
two characteristic minima at approximately 210 nm and 220 nm, and a maximum peak at
190 nm
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Fig 3. Saturation binding analysis of biotinylated glu-plasminogen to immobilised
recombinant PAMNS13 mutant proteins. Biotinylated glu-plasminogen binding to
immobilised recombinant protein (A PAMNS13; B PAMNS13[K98 K111]; C PAMNS13[K98
R101 H102 E104 K111]; D PAMNS13[K98 R101 H102 E104 K111 R114 H115]; E PAMNS13[R101 H102];
F PAMNS13[R101 H102 R114 H115] ) was measured in the absence (▼, total binding) and
presence (●, non-specific binding) of a 50 fold molar excess of unlabelled gluplasminogen. Specific binding (■) was determined by subtracting non-specific binding
from total binding at each concentration. A one-site hyperbolic binding function was
fitted to the data (p < 0.05), from which the binding dissociation constants were
determined. Error bars represent the standard error of the mean (SEM; n = 3).
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Fig 4. Competition of glu-plasminogen binding to immobilised recombinant PAM
variants with fluid phase PAMNS13. Binding of biotinylated glu-plasminogen to
immobilised A PAMNS13, B PAMNS13[K98 K111]; C PAMNS13[K98 R101 H102 E104 K111], and
D PAMNS13[R101 H102] was measured in the presence of varying concentrations of
unlabelled fluid phase PAMNS13. Data points are the mean values of triplicate readings,
with error bars indicating the standard error of the mean (SEM; n=3). One-site
competition analysis was performed on data for all recombinant proteins; this analysis
was used to determine the concentration of PAMNS13 required to inhibit binding of
biotinylated glu-plasminogen by 50% (EC50).
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